Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox
 


  Conjugate Vaccines

This technology of conjugate vaccine production was first used for Haemophilus influenzae type b vaccines (Hib) and has succeeded in virtually eliminating haemophilus influenzae meningitis in vaccinated children over the last decade. (9,13,18)

A new generation of so-called conjugate vaccines is now available for routine immunization programs against serogroup C meningitis. Conjugate vaccines induce a long-lasting immune response across a wider age range than non-conjugate polysaccharide vaccines. The result is a higher level of protection against group C meningococcal meningitis. A vaccination campaign against group C meningococcal meningitis was carried out in the UK in 1999- 2000, resulting in an 75% reduction in the incidence of meningitis C. (7,8,9,10,13,14,22)


 » Printversion

 
 
  » find


 

Baxter initiates clinical study with cell-based candidate H5N1 Pandemic Vaccine
» read more

Baxter to participate in development of cell-based vaccines for U.S. Department of Health and Human Services
» read more

Baxter Receives Contract From National Health Service in United Kingdom to Produce Stockpile of H5N1 Flu Vaccine
» read more

 
Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,